These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
284 related items for PubMed ID: 2943606
21. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505 [Abstract] [Full Text] [Related]
22. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease. Lubin V, Charbonnel B, Bouchard P. Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771 [Abstract] [Full Text] [Related]
23. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome. van der Westhuizen S, van der Spuy ZM. Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098 [Abstract] [Full Text] [Related]
24. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. Haning RV, Austin CW, Carlson IH, Kuzma DL, Zweibel WJ. Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830 [Abstract] [Full Text] [Related]
25. Conventional dose intravenous pulsatile GnRH therapy does not induce ovulation in polycystic ovarian disease. Wilson JM, Traub AI, Sheridan B, Thompson W, Atkinson AB. Acta Endocrinol (Copenh); 1988 Mar; 117(3):289-94. PubMed ID: 2968035 [Abstract] [Full Text] [Related]
26. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF. J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784 [Abstract] [Full Text] [Related]
27. Normal ovarian function in a mild form of late-onset 3 beta-hydroxysteroid dehydrogenase deficiency. Medina M, Herrera J, Flores M, Martin O, Bermúdez JA, Zárate A. Fertil Steril; 1986 Dec; 46(6):1021-5. PubMed ID: 3023147 [Abstract] [Full Text] [Related]
28. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. Adams JM, Taylor AE, Crowley WF, Hall JE. J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031 [Abstract] [Full Text] [Related]
29. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Palatsi R, Reinilä M, Kivinén S. Acta Derm Venereol; 1986 Sep; 66(3):225-30. PubMed ID: 2426899 [Abstract] [Full Text] [Related]
30. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders. Saffan D, Seibel MM. Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681 [Abstract] [Full Text] [Related]
31. Role of androgens in the regulation of the human menstrual cycle. Rossmanith WG, Schenkel B, Benz R. Gynecol Endocrinol; 1994 Sep; 8(3):151-9. PubMed ID: 7847099 [Abstract] [Full Text] [Related]
32. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism. Toscano V, Bianchi P, Balducci R, Guglielmi R, Mangiantini A, Lubrano C, Sciarra F. Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185 [Abstract] [Full Text] [Related]
39. The frequency of pulsatile luteinizing hormone-releasing hormone treatment and luteinizing hormone and follicle-stimulating hormone secretion in women with amenorrhea of suprapituitary origin. Lambalk CB, Schoemaker J, van Rees GP, van Dieten HA. Fertil Steril; 1989 Mar; 51(3):416-22. PubMed ID: 2493401 [Abstract] [Full Text] [Related]
40. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]